SHORT MINI FUTURE - MODERNA | Market Closed - Swiss Exchange 08:50:00 07/06/2024 pm IST | ||
| 1.52 CHF | +5.56% |
|
| Current month | -5.59% | ||
| 1 month | -28.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 1.52 | +5.56% |
| 06/24/06 | 1.44 | -5.88% |
| 05/24/05 | 1.53 | -6.71% |
| 04/24/04 | 1.64 | +5.81% |
| 03/24/03 | 1.55 | -3.73% |
Delayed Quote Swiss Exchange
Last update June 07, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| LMRNJB | |
| ISIN | CH1242784218 |
| Date issued | 19/01/2023 |
| Strike | 235.1 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.99 CHF |
|---|---|
| Lowest since issue | 0.65 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.65% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
151
USD
Average target price
143.9
USD
Spread / Average Target
-4.68%
- Stock Market
- Certificates
- LMRNJB Certificat
